Cargando…
Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma
Introduction. Primary central nervous system lymphoma is an uncommon form of extranodal non-Hodgkin’s lymphoma, with increasing incidence, a relatively aggressive course and a poor 5-year survival. Because of its localization, the therapeutic compounds used in this disease must be able to pass throu...
Autores principales: | Deak-Mihaly, Dalma, Iluta, Sabina, Pasca, Sergiu, Jitaru, Ciprian, Roman, Andrei, Andries, Alexandra, Padurariu-Covit, Monica, Petrushev, Bobe, Vasilache, Anca, Bojan, Anca, Zdrenghea, Mihnea, Dascalescu, Angela, Antohe, Ion, Colita, Anca, Colita, Andrei, Dima, Delia, Tanase, Alina, Tomuleasa, Ciprian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509719/ https://www.ncbi.nlm.nih.gov/pubmed/34640501 http://dx.doi.org/10.3390/jcm10194483 |
Ejemplares similares
-
Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
por: Deak, Dalma, et al.
Publicado: (2019) -
Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO)
por: Colita, Andrei, et al.
Publicado: (2023) -
Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases
por: Radu, Letitia-Elena, et al.
Publicado: (2020) -
Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020) -
The Predictive Role of Modified Early Warning Score in 174 Hematological Patients at the Point of Transfer to the Intensive Care Unit
por: Constantinescu, Catalin, et al.
Publicado: (2021)